United Therapeutics (UTHR)

United Therapeutics markets several PAH therapies in the United States, including Tyvaso DPI, an inhaled dry-powder formulation of treprostinil; Remodulin, an injectable treprostinil therapy; and Orenitram, an oral extended-release treprostinil tablet. It also sells Adcirca, a tadalafil therapy for PAH, and Unituxin, an antibody treatment used in high-risk neuroblastoma. Tyvaso has become a central product for the company, with the dry-powder device format aimed at making inhaled therapy more convenient for eligible patients.

Beyond its marketed medicines, United Therapeutics is distinctive for its long-running interest in addressing the shortage of transplantable organs. The company invests in organ manufacturing technologies, including xenotransplantation, regenerative medicine, and related platforms intended to expand the future supply of lungs and other organs. This creates a business profile that combines a revenue-generating rare disease pharmaceutical franchise with ambitious research programmes in transplantation.

Most of the company’s revenue is generated in the United States, although it also has international activities. Its market position depends on clinical differentiation, physician adoption, pricing and reimbursement, patent protection, manufacturing execution, and the ability to extend its pulmonary hypertension franchise while advancing longer-term organ-focused innovation.